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BACKGROUND. Biliary tract carcinoma is an aggressive cancer, with median survival
rarely exceeding 6 months. There is currently no established palliative standard of
care. A Phase II trial was conducted to study a combination of oral capecitabine
and gemcitabine (CapGem) as ﬁrst-line therapy in patients with advanced and/or
metastatic biliary carcinoma.
METHODS. Patients with unresectable or metastatic intrahepatic or extrahepatic
biliary duct carcinoma and gallbladder carcinoma were enrolled. Eligible patients
had histologically or cytologically conﬁrmed, measurable adenocarcinoma and
had not received prior therapy with capecitabine or gemcitabine. Treatment con-
sisted of intravenous (i.v.) gemcitabine (1000 mg/m2 on Days 1 and 8) plus oral
capecitabine (650 mg/m2 twice daily on Days 1–14) every 3 weeks for up to 6 cycles.
Tumor response, survival, and safety were determined.
RESULTS. A total of 44 patients were evaluable. Primary tumor sites were: intrahe-
patic (n  14) and extrahepatic biliary duct (n  16); gallbladder (n  7); and
ampulla (n  7). Fourteen (32%) patients had a partial response and 15 (34%)
patients had stable disease. Median time to disease progression and overall sur-
vival were 6.0 (range, 3.8–8.1) and 14 (range, 11.4–16.6) months, respectively. The
1-year survival rate was 58%. No Grade 4 adverse events were seen. Transient
Grade 3 neutropenia/thrombocytopenia and manageable (almost invariably Grade
2) nausea, diarrhea, and hand–foot syndrome were the most common adverse
events.
CONCLUSIONS. CapGem is an active and well tolerated ﬁrst-line combination
chemotherapy regimen for patients with advanced/metastatic biliary tract carci-
noma that offers a convenient home-based therapy. Cancer 2005;104:2753–8.
© 2005 American Cancer Society.
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B iliary tract carcinomas are aggressive tumors with a poor progno-sis. While surgical resection of the primary tumor and the areas of
local extension remains the most effective therapy, 25% of patients
will be resectable at presentation.1–4 The remaining 75% will receive
palliative therapy, with a median survival of approximately 6 months.
In addition, those undergoing potentially curative resections experi-
ence high rates of disease recurrence and are generally incurable at
recurrence. To date, chemotherapy has had limited impact on this
disease, because of the absence of agents with substantial activity in
these tumors and the overall morbidity of this patient population.
5-Fluorouracil (5-FU) has been considered the mainstay of pal-
liative chemotherapy; however, response rates from Phase III trials
are in the range of 0–10%.5,6 Continuous infusion of 5-FU offers
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several potential advantages over intravenous (i.v.)
bolus administration, but impracticality limits its use.
Capecitabine (Xeloda, Hoffman La Roche, Nutley, NJ)
is an oral ﬂuoropyrimidine that generates 5-FU selec-
tively in tumor tissues. This selectivity is achieved by
the enzyme thymidine phosphorylase (TP), which is
responsible for the ﬁnal conversion of capecitabine to
5-FU and is found at much higher levels in tumors
compared with normal tissues.7–10 Capecitabine offers
the possibility of continuous tumor exposure to 5-FU
by preferential activation at the tumor site, while min-
imizing the potential exposure of healthy body tissues
to systemic 5-FU.
The nucleoside analog gemcitabine has shown
single-agent activity in Phase II trials in biliary tract
carcinoma with response rates ranging from
8–36%.11–15 Gemcitabine and 5-FU in combination
appear to have synergy in preclinical studies.16 A
Phase I–II trial by Hidalgo et al.,17 evaluating 5-FU
administered in a protracted i.v. infusion plus weekly
gemcitabine in patients with pancreatic carcinoma,
showed promising activity. Other than the dose-limit-
ing toxicities of neutropenia or thrombocytopenia, the
regimen was well tolerated. On the basis of these
ﬁndings, the combination of capecitabine and gem-
citabine (CapGem) warrants investigation for the
treatment of biliary tract carcinoma. The present
study was designed to evaluate CapGem activity and
tolerability in patients with advanced/metastatic bili-
ary tract carcinoma.
MATERIALS AND METHODS
The study recruited patients between January 2001
and June 2003. Eligible patients were between 18 and
75 years of age and had histologically or pathologically
conﬁrmed advanced or metastatic, bidimensionally
measurable biliary tract carcinoma not amenable to
curative surgery (WHO criteria). Patients had not pre-
viously received chemotherapy for their disease. Pa-
tients were required to have a Karnofsky Performance
Status (KPS) 70%, adequate renal, hepatic, and he-
matologic functions, and a life expectancy of 3
months. Serum bilirubin was up to 3 the upper limit
of normal. A detailed medical history, physical and
neurologic examinations, chest X-ray, spiral com-
puted tomographic (CT) scan of the abdomen, and
ECG were performed within the 2 weeks before study
commencement. Run-in procedures, including vital
signs and clinical laboratory tests, were performed
within 7 days before the start of chemotherapy. All
patients gave written informed consent to participate.
The trial protocol received local ethical board ap-
proval and the study was conducted according to the
principles of the Declaration of Helsinki and its sub-
sequent amendments.
Treatment and Dose Modiﬁcations
Most (82%) patients were treated on an outpatient
basis. Gemcitabine (Gemzar; Eli Lilly, Indianapolis,
IN) was given as a 30-minute i.v. infusion on Days 1
and 8 of each cycle at a dose of 1000 mg/m2. Capecit-
abine (Xeloda, Hoffman La Roche) was administered
orally at a dose of 650 mg/m2 twice daily on Days 1–14
followed by 1 week of rest. Cycles were repeated every
3 weeks unless patients experienced treatment-related
adverse effects. Standard antiemetic treatment with
granisetron or ondansetron was administered to all
patients. Prophylactic administration of recombinant
human granulocyte colony-stimulating factor (rhG-
CSF) was not allowed. Treatment was administered for
at least six cycles or until disease progression, at the
physicians’ discretion. Dose adjustment criteria were
based on hematologic parameters. For Grade 3/4 afe-
brile neutropenia, subsequent cycles were repeated
with rhG-CSF prophylactic administration. In cases of
febrile neutropenia or Grade 3/4 neutropenia despite
the prophylactic administration of rhG-CSF, gemcit-
abine and capecitabine doses were each reduced by
25%. For Grade 3/4 thrombocytopenia lasting 5
days, doses of both drugs were reduced by 25%. The
dose of capecitabine was reduced by 25% in case of
Grade 3/4 diarrhea or hand–foot syndrome (HFS).
Patients with complete remission (CR), partial re-
mission (PR), or stable disease (SD), and who were
tolerating treatment well, were treated for up to six
cycles. Those with clearly documented progressive
disease (PD) were taken off treatment at the time of
progression. Responding patients (CR or PR) or those
with SD after 18 weeks were followed until PD and
were able to continue on CapGem at the discretion of
the investigator.
Efﬁcacy
Tumor assessments, according to WHO criteria,18
were performed at 6-week intervals by the investiga-
tors. Tumor lesions were assessed by CT scan, X-rays,
or magnetic resonance imaging (MRI), and objective
tumor response was based on the dimensions of mea-
surable marker lesions, measured by the same radiol-
ogist throughout the study. Tumor response was also
determined by an Independent Review Committee
(IRC). Time to disease progression (TTP) was calcu-
lated as the time from ﬁrst treatment to the time the
patient was ﬁrst recorded as having PD, or the date of
death if the patient died before PD was demonstrated.
Survival was monitored every 3 months after the pa-
tient completed treatment.
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Safety
Safety was monitored throughout the study and for 28
days after the last study treatment. Adverse events
were graded according to the National Cancer Insti-
tute–Common Toxicity Criteria (NCI-CTC). HFS was
graded as in previous capecitabine studies.19 Patients
were educated to recognize adverse effects Grade 2
and interrupted capecitabine until further instructed
by their physician.
Statistics
The response rate was expected to be approximately
25%; a sample size of 38 was calculated by Fleming
single-stage design20 to ensure at least 80% power for
proving lack of efﬁcacy if the true response rate was
less than 25%. Estimating a dropout rate of 15%, a
total of 44 patients were recruited to ensure that at
least 38 patients were evaluable. TTP and survival
were analyzed by the Kaplan–Meier product limit
method. Patients who received at least one dose of
study medication were included in the intention-to-
treat (ITT) analysis. Those who did not receive at least
one dose of study medication or for whom no follow-
up safety information was available were excluded
from the safety analysis.
RESULTS
Patient Characteristics
Of the 45 patients enrolled, 44 (26 women and 18 men)
received at least one dose of CapGem and were evalu-
able for efﬁcacy and safety (ITT population). One pa-
tient withdrew consent during the screening period
and did not receive CapGem. As shown in Table 1, the
majority of patients (77%) had Stage IV disease and
the most commonly affected metastatic sites were the
liver (52%) and lymph nodes (45%). Thirty-two per-
cent of patients had undergone one or more type of
surgical intervention for their cancer.
Efﬁcacy
Response data according to the investigator assess-
ment are summarized in Table 2. The objective re-
sponse rate (ORR) was 32% (95% conﬁdence interval
[CI]: 19–48%), all of which were PRs (n  14). The
same ORR was conﬁrmed by the IRC. According to the
investigators, 15 (34%) patients had SD. IRC con-
ﬁrmed 13 (30%) patients with SD. For patients with
gallbladder carcinoma (n  7), ORR was 57%. For
patients with intrahepatic (n 14) and extrahepatic (n
 16) bile duct and ampulla (n  7) carcinoma, ORRs
were 36%, 25%, and 29%, respectively.
The median TTP was 6.0 months (95% CI: 3.0–8.1
mos, Fig. 1) and the median overall survival (OS) was
14 months (95% CI: 11.4–16.6 mos, Fig. 2). The 1-year
actuarial survival rate was 58%.
The median duration of treatment for all patients
was 63 days (range, 7–238 days). Eighteen (41%) pa-
tients were treated for at least 18 weeks; of these, 10
(23%) were treated for more than 18 weeks in the
continuation phase.
Safety
Nonhematologic adverse events are summarized in
Figure 3. Grade 2/3 nonhematologic adverse events
were: nausea (12/2%), HFS (9/0%), vomiting (8/3%),
constipation (5/2%), anorexia (3/2%), general weak-
ness (3/0%), insomnia (2/0%), and diarrhea (2/0%).
Hematologic adverse events are summarized in Figure
TABLE 1
Baseline Patient and Disease Characteristics (n  44 Patients)
Characteristic Value (%)
Age (yrs)
Median 62
Range 41–75
Gender (no. of patients)
Male 18 (41)
Female 26 (59)
Karnofsky Performance status, %
Median 90
Range 70–100
Disease stage, no. of patients
Locally advance 10 (23)
Metastatic 34 (77)
Primary tumor site, no. of patients
Intrahepatic bile ducts 14 (32)
Extrahepatic bile ducts 16 (36)
Gallbladder 7 (16)
Ampulla 7 (16)
Location of metastatic sites
Liver 23 (52)
Lymph nodes 20 (45)
Lung 9 (20)
Bone 6 (14)
Other 4 ((9)
Patients with 1 surgical intervention 10 (23)
TABLE 2
Antitumor Activity (ITT Analysis; n  44)
Response (investigator
assessment) No. % (95% CI)
Overall response 14 32 (19–48)
Complete response 0 0
Partial response 14 32 (19–48)
Stable disease 15 34 (20–50)
Progressive disease 15 34 (20–50)
ITT, intention to treat.
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4. Grade 3 neutropenia and Grade 3 thrombocytope-
nia occurred in 11% and 9% of patients, respectively.
Three patients developed febrile episodes. No Grade 4
nonhematologic or hematologic adverse events were
seen. No patient discontinued treatment because of
abnormal laboratory values. No deaths attributable to
adverse events occurred during the study. There were
23 deaths reported during the study, the majority of
which occurred more than 28 days after the end of the
planned treatment schedule. All of the deaths were
related to PD.
A median of four courses of treatment (range,
1–16 courses of treatment) were given. During Cycle 1,
97% (range, 86–100%) and 99% (range, 87–100%) of
the planned doses of capecitabine and gemcitabine,
respectively, were given. During Cycle 2, the corre-
sponding values for capecitabine and gemcitabine
were 95% (range, 83–100%) and 96% (range, 85–100%),
respectively. Despite the need for dose modiﬁcations,
90% of patients received all 3 weeks of treatment with
both drugs during the ﬁrst two cycles of therapy.
DISCUSSION
The current ﬁndings show that CapGem combination
chemotherapy is active and very well tolerated as a
ﬁrst-line treatment in patients with advanced and/or
metastatic biliary tract carcinoma. The ORR was 32%
and an additional 30% of patients had durable SD.
This compares favorably with results previously re-
ported for 5-FU/gemcitabine combinations in pa-
tients with advanced biliary tract carcinoma. Recently,
Knox et al.21 evaluated continuous i.v. infusion of
5-FU (200 mg/m2 for 21 days) plus gemcitabine (900
mg/m2 on Days 1, 8, and 15) every 4 weeks in 27
patients with advanced biliary tract adenocarcinoma:
ORR was 33% and 30% of patients achieved SD. Geb-
bia et al.22 treated 22 biliary carcinoma patients with a
combination of gemcitabine (1000 mg/m2 on Days 1
and 8) and 5-FU (400 mg/m2 i.v. bolus followed by 600
mg/m2 by 22-hr continuous i.v. infusion)/leucovorin
(100 mg/m2 i.v. for 2 hr) every 3 weeks: ORR was 36%
FIGURE 1. Time to disease progression.
FIGURE 2. Overall survival.
FIGURE 3. Nonhematologic adverse events.
FIGURE 4. Hematologic adverse events.
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and 23% achieved SD. Adverse events were mild in
both these studies and similar to our results.
The usual limitations of cross-study comparisons
should be taken into account when interpreting efﬁ-
cacy results. However, it is interesting to note that the
ORR was better in the present study than the 21%
observed in 38 Korean patients with advanced biliary
carcinoma receiving capecitabine (1250 mg/m2 twice
daily on Days 1–14) plus cisplatin (60 mg/m2 on Day 1)
every 3 weeks23 and the 24% observed in 25 French
patients with advanced/metastatic biliary carcinoma
who were treated with continuous i.v. infusion of 5-FU
(1000 mg/m2/day for 5 days) plus cisplatin (100
mg/m2 on Day 2) every 3 weeks.24
Interpretation of survival data in such relatively
small groups of patients is difﬁcult because of poten-
tial selection bias. Nonetheless, the median TTP (6
mos) and OS (14 mos) for patients receiving CapGem
in the current study is comparable to median TTP and
OS (5.7 and 15.4 mos, respectively) previously re-
ported by Andre et al.25 on behalf of the GERCOR
group, who treated 33 patients with advanced biliary
adenocarcinoma and achieved good performance sta-
tus using GEMOX: gemcitabine (1000 mg/m2 on Day
1) plus oxaliplatin (100 mg/m2 on Day 2) every 2
weeks. However, larger randomized trials are required
to conﬁrm the comparability of these ﬁndings.
In addition to antitumor efﬁcacy, safety and con-
venience are critically important issues for the choice
of new treatment combinations. The current CapGem
regimen has the advantage over continuous i.v. 5-FU
plus either gemcitabine or cisplatin of convenience
and practicability, and has clear potential to reduce
healthcare resource expenditure. This is because
capecitabine is administered orally and avoids the
complications related to use of an implanted catheter
required for the continuous i.v. administration of
5-FU. Rates of venous thrombosis and central line
infection were 7% and 9%, respectively, in the study by
Knox et al.,21 which combined continuous i.v. infusion
of 5-FU plus gemcitabine: this complication ac-
counted for almost half of the treatment-related seri-
ous adverse events with 5-FU/gemcitabine. Toxicity
has been a signiﬁcant problem with different sched-
ules of 5-FU/cisplatin regimes and needs to be im-
proved. One of the better-tolerated 5-FU plus cisplatin
regimens was reported by Taieb et al.,26 who incorpo-
rated the de Gramont 5-FU regimen (5-FU 400 mg/m2
i.v. bolus followed 22-hr continuous i.v. infusion of
600 mg/m2 on 2 consecutive days) with a modest dose
of cisplatin (50 mg/m2 on Day 2). They treated 29
patients with advanced/metastatic biliary carcinoma.
The ORR was 34%, which is comparable to our result.
However, more Grade 3/4 hematologic toxicity (41%)
was reported, compared with the rate of 11% seen in
our study. Median OS was 9.5 months, which is infe-
rior to our ﬁndings (14 mos), although it is difﬁcult to
compare survival between single-arm studies.
Biliary tumors can occur anywhere in the hepato-
biliary system and are often classiﬁed according to
location. In the present study, gallbladder carcinoma
appeared to respond better than cholangiocarcinoma,
although response rates did not differ statistically,
possibly because of the relatively small number of
patients included in the study. The response rates
according to primary site in the present study are in
line with those previously mentioned in a GERCOR
group study with GEMOX.25 However, it is important
to note that cholangiocarcinoma in this study had
more extensive disease than those with gallbladder
carcinoma. Further study will be needed to clarify
response to chemotherapy according to primary tu-
mor sites.
In conclusion, the CapGem combination is active
as a ﬁrst-line chemotherapy in patients with advanced
and/or metastatic biliary tract carcinoma. In this pop-
ulation, a favorable toxicity proﬁle is of great impor-
tance, and our study indicated that CapGem was well
tolerated. The convenience of administration of the
CapGem combination needs to be stressed, as it per-
mits home-based therapy. A conﬁrmatory Phase II
study will be needed to validate these promising re-
sults with CapGem in this setting.
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